Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Executive Changes (Apr 4, 2025)

Reports
Leadership Changes·Regulation FD·Exhibits & Filings
Filing Date
Filed April 4, 2025
Period End
April 2, 2025
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed April 4, 2025. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) filed this Current Report on Form 8-K on April 4, 2025 to announce a leadership change in its executive team.

On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as Chief Medical Officer, effective June 2, 2025. Dr. Roberts had served as Chief Medical Officer for the past seven years and, as previously announced in July 2023, had decided to retire for personal reasons.

She will remain with the Company in a strategic advisory role after the handover. According to the attached press release (Exhibit 99.1), Dr. Keswani has more than 20 years of pharmaceutical industry experience and will lead clinical development and medical affairs. His previous roles include President and CEO of ImmunoBrain, Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb.

CEO Kyle W. Gano, Ph.D., said the appointment extends the Company's reach beyond small molecule medicines into new modalities. The press release also credits Dr. Roberts with leading indication expansion for INGREZZA (valbenazine), the crinecerfont program that led to FDA approval of CRENESSITY (crinecerfont), and Phase 2 proof-of-concept studies for osavampator and NBI-1117568, both of which are moving into registrational programs this year.

Key Highlights

  1. Sanjay Keswani, M.D. appointed Chief Medical Officer effective June 2, 2025, succeeding Eiry W. Roberts, M.D.
  2. Dr. Roberts served as Chief Medical Officer for seven years and will remain with the Company in a strategic advisory role
  3. Dr. Roberts' retirement decision was previously announced in July 2023 and cited personal reasons
  4. Dr. Keswani brings more than 20 years of industry experience, including senior R&D roles at Hoffman La Roche and Bristol-Myers Squibb
  5. Dr. Keswani will lead clinical development and medical affairs, with a stated focus on new modalities beyond small molecules
  6. Dr. Roberts oversaw INGREZZA indication expansion, the CRENESSITY development program, and osavampator and NBI-1117568 Phase 2 studies moving into registrational programs in 2025
  7. The appointment was disclosed under Items 5.02 and 7.01 and furnished, not filed, under Item 7.01

Frequently Asked Questions

  1. Who is replacing the current Chief Medical Officer, and when does the change take effect?

    Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer, effective June 2, 2025. Dr. Keswani agreed to the role on April 2, 2025.

  2. What happens to Dr. Roberts after the transition?

    Dr. Roberts will remain with Neurocrine Biosciences in a strategic advisory role following her succession by Dr. Keswani.

  3. Why is Dr. Roberts leaving the Chief Medical Officer position?

    The filing states that Dr. Roberts notified the Company in July 2023 of her decision to retire for personal reasons. She agreed to stay in the role until her replacement was onboarded.

  4. What experience does Dr. Keswani bring to the role?

    According to the press release, Dr. Keswani has more than 20 years of pharmaceutical industry experience, including R&D leadership roles at Hoffman La Roche and Bristol-Myers Squibb and the position of President and CEO of ImmunoBrain. He will continue to serve on ImmunoBrain's board of directors.

  5. What does the leadership change mean for the company's pipeline?

    The CEO said Dr. Keswani's contributions will extend the Company's reach beyond small molecule medicines, enabling exploration of new modalities across its therapeutic areas. The press release notes that osavampator and NBI-1117568 are moving into registrational programs this year, and the forward-looking statements flag the risk that the leadership transition may not follow currently anticipated timelines.